Abstract: Objective This clinical trial was conducted to evaluate the efficacy and safety of glecaprevir/pibrentasvir in treatment of patients with HCV mono-infection and HIV/HCV co-infection. Methods 25 patients with hepatitis C virus infection, including chronic hepatitis C (CHC) in 22 cases and compensated liver cirrhosis (CLC) in 3 cases, and 27 patients with HIV and HCV co-infection, including CHC in 25 cases and CLC in 2 cases, were enrolled in this study between April 2021 and December 2021, and all received glecaprevir/pibrentasvir antiviral therapy for eight to twelve weeks. All patients were followed-up for 12 weeks. Results The percentages of intravenous drug users in the two groups were 60.0% and 63.0%; the sustained virological response (SVR) at 12 weeks after treatment(SVR 12) in patients with HCV infection was 92.0%, not significantly different compared to 88.9% (P=1.000) in patients with HIV/HCV co-infection; the glecaprevir/pibrentasvir therapy was well tolerated in the two groups, and there was no severe adverse events leading to the adjustment or suspension of the anti-viral therapy regimen. Conclusion The administration of glecaprevir/pibrentasvir anti-viral therapy has a promising short-term efficacy and safety in the treatment of patients with HCV mono-infection and HIV/HCV co-infection.

Key words: Hepatitis C virus, AIDS, Co-infection, Direct antiviral agents, Glecaprevir/pibrentasvir, Therapy, Safety